DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
...
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05496335
- Locations
- 🇺🇸
The Eye Research Foundation /ID# 244430, Newport Beach, California, United States
🇺🇸DeNova Research /ID# 244421, Chicago, Illinois, United States
🇺🇸Bellaire Dermatology Associates /ID# 244428, Bellaire, Texas, United States
Treatment of Gastrocnemius Tightness and Subsequent Chronic Plantar Fasciitis With Botulinum Toxin A
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05218785
- Locations
- 🇳🇴
Oslo University Hospital, Orthopedic Department Ullevål, Oslo, Norway
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT05216250
- Locations
- 🇺🇸
Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 231731, Phoenix, Arizona, United States
🇺🇸Accel Research Sites - Neurology and Neurodiagnostics of Alabama, LLC /ID# 240472, Hoover, Alabama, United States
🇺🇸University of Arizona /ID# 239781, Tucson, Arizona, United States
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
- Conditions
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT05158166
- Locations
- 🇺🇸
UCSF, San Francisco, California, United States
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 83
- Registration Number
- NCT05141006
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Mobile /ID# 241002, Mobile, Alabama, United States
🇺🇸Urology Centers of Alabama /ID# 243600, Homewood, Alabama, United States
🇺🇸Sun Kim Urology /ID# 257566, Buena Park, California, United States
BOTOX® Cosmetic and Skin Health.
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Andreas Nikolis
- Target Recruit Count
- 34
- Registration Number
- NCT05138835
- Locations
- 🇨🇦
Erevna Innovations Inc, Montreal, Quebec, Canada
Ultrasound-Guided Stellate Ganglion Block With Botulinum
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT05099835
- Locations
- 🇪🇬
Emad Zarief Kamel Said, Assiut, Egypt
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Medytox Korea
- Target Recruit Count
- 318
- Registration Number
- NCT05059587
- Locations
- 🇰🇷
Chung-Ang Univ. Hospital, Seoul, Dongjak-gu, Korea, Republic of
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 775
- Registration Number
- NCT05028569
- Locations
- 🇺🇸
Albuquerque Clinical Trials, Inc. /ID# 231101, Albuquerque, New Mexico, United States
🇺🇸Duplicate_University Of Cincinnati Medical Center /ID# 231739, Cincinnati, Ohio, United States
🇨🇿Fakultní Nemocnice U Sv. Anny V Brně /ID# 232213, Brno, Brno-mesto, Czechia
Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 1
- Registration Number
- NCT05006417
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.